Up to now there was a lack of early biomarkers for acute myocardial infarction, to allow establishing a diagnosis and thus choosing the best treatment to prevent the worst consequences of this infarction.
Our scientists from CSIC and the Catalan Institute of Cardiovascular Sciences have discovered that in sera from patients with acute myocardial infarction there are modifications in the levels of some isoforms of the apolipoprotein J (Apo J) and that these changes are detectable within 6 hours after the onset of the infarct.
Thus, the levels of some glycosilated isoforms of Apo J show a 2-fold increase and the levels of others are reduce by 50% in sera of patients with acute myocardial infarction, when compared to healthy individuals.
These isoforms are currently being further characterised and antibodies against them are being generated to facilitate the development of a diagnostics test.
Main features and advantages
PCT patent application filed
An exclusive patent licence is preferred, but we are open to discuss other approaches
Dr Jose Pablo Zamorano
Life Sciences Licensing Coordinator
Spanish public research organisation with 126 centres covering all knowledge areas and highly active in collaborating with the industry.View profile
Clients in focus...